A Powerful New Weapon in the Fight against Flu
Demonstrated to be 12 Times More Effective Than the Yellow Pills Against Tested Strains of Influenza Virus Type A;
Demonstrated to be effective against Influenza Virus Type B, Hand-Foot-Mouth Disease (HFMD) - Enterovirus 71 and Coxsackie A16; and other Viral Pathogens;
Extensive laboratory testing reported in peer reviewed scientific literature;
100% organic and natural, derived from an organic nutritive resource with Naturland organic certification, Germany;
Produced Under Strict International ISO 9001:2000 Quality Assurance Guidelines. Adhere to International GMP standard.
Safe and non-toxic, even at high dosage levels.
Ideal for Travel, Work, and Home
Suitable for Both Adults and Children
Under license to distribute exclusively from
Green Energy Biotech Corporation Limited
An Effective Firewall Against Flu
At best, the flu is like a very bad cold. It can stop you dead in your tracks with numbing fatigue, fever, congestion, coughing, diarrhea and an endless procession of miserable symptoms. At its very worst, the flu can kill millions of otherwise healthy people in a single season.
During World War I, the global “Spanish flu” pandemic was so severe that for a time, more soldiers died fighting the microscopic virus at war within their bodies than from fighting one another on the battlefields of Europe with a broad consensus that between 40 and 100 million may have perished by the time the pandemic had run its course in 1919.
Epidemiologists – Scientists that study the health of populations rather than individuals – are fairly certain that another influenza pandemic is imminent. The World Health Organization (WHO) asserts that, “Since late 2003, the world has moved closer to a pandemic than at any time since 1968, when the last of the previous century’s three pandemics occurred.”
Like earthquakes, the exact timing of a flu pandemic is impossible to predict. But based on years of careful tracking, an international community of virus detectives believes that the next great flu outbreak will likely start in Southern Asia, as bird or “avian” viruses mutate into agents of human disease.
Over the past few years, an extremely lethal flu virus designated “Avian influenza A H5N1” has prompted the destruction of millions of ducks, chickens and other domesticated birds in a desperate effort to limit the potential spread of this virus to humans.
Experts fear that if this deadly strain of virus mutates such that it is readily contracted and conveyed by humans, we may face another global pandemic of overwhelming proportions. The WHO warns that, “During 2005, ominous changes have been observed in the epidemiology of the disease in animals. Human cases are continuing to occur, and the virus has expanded its geographical range to include new countries, thus increasing the size of the population at risk. Each new human case gives the virus an opportunity to evolve towards a fully transmissible pandemic strain.”
A Ticking Time Bomb
Most powerful anti-viral drugs, like yellow and white pills by Pharmaceutical Company, are extremely toxic, prohibitively expensive and may only be effective against specific viral strains.
While it is true that highly effective vaccines can often be produced that confer protection against a new viral threat, by the time the virus is identified and a vaccine is produced, it is often too late to be of much use. Either the population of infected individuals has grown too large to adequately protect or the virus has already mutated, rendering the vaccine partially or wholly ineffective.
Why are we so worried about Influenza A, H1N1 flu when hundreds of thousands die every year from seasonal epidemics?
Global H1N1 Flu Cases Leap Past 100,000
Posted: 22 July 2009 0315 hrs by Channelnewasia
US health authorities said Friday that at least one million people in the United States have had H1N1 flu, or around 50 times more than the number of cases officially reported by the US Centres for Disease Control and Prevention (CDC).
On 3 July, 2009, it was reported that a genetic mutation of Influenza A (H1N1) flu that is resistant to the anti-viral Tamiflu has also been discovered in Hong Kong, Japan and Denmark. The patients have to be treated with other remedy.
A POWERFUL NEW FLU AND VIRUS REMEDY
NIGIRO™ BLUE TINT
Cholesterol reduction and related effects
A patented form of purified phycocyanin (“APC”) derived from Spirulina is now available as a flu fighting agent called NigiroTM Blue Tint. And will be available in a variety of forms including capsules, lozenges, tincture and specially formulated oral granules for children. Nigiro™ Blue Tint may be used on a daily basis to provide ongoing firewall protection against the flu and certain other disease-causing viruses. Nigiro™ Blue Tint may also be used at the first sign of viral infection to slow the spread of the virus and assist the body’s natural ability to combat and control it. Nigiro™ Blue Tint may be particularly helpful when flying on airplanes or entering into other crowded spaces. It creates a physical coating in the throat that can act as a barrier against infection. Children’s Granules, naturally rich in vitamins, minerals, amino acids and other nutrients, are specially made to provide immune support for the intestinal tract, the site of many juvenile viral infections including Hand-Foot-Mouth Disease - Enterovirus 71 and Coxsackie A16, potentially deadly conditions that often affect children.
INFLUENZA VIRUS REPLICATION CYCLE
Briefly, the virus initially binds to its cell-surface receptor and is internalised into endosomes (cytoplasmic vesicles), where the low pH of the environment triggers virus fusion and uncoating. The uncoated vRNPs then enter the nucleus of the host cell for virus replication. Following virus replication, the vRNPs leave the nucleus and move to the plasma membrane, where they associate with viral glycoproteins before final budding and release. Each of these transport events is considered below, in relationship to our current understanding of influenza virus pathogenesis and treatment.
Nigiro™ Blue Tint creates a physical coating in the cell (Sialic acid) outer wall and prevents the virus from attaching and entering it. The white blood cells will then defend the body against Influenza Virus and destroy them. By taking Nigiro™ Blue Tint 1 to 2 c.c, it can protect our cells for 24 hours effectively.
HOW EFFECTIVE IS NIGIRO™ BLUE TINT?
In response to fears about a global avian flu pandemic, the media have featured a number of stories about a prescription anti-flu drug “Yellow Pills”. Governments around the world, including the U.S., have been stockpiling the yellow pills against a possible future outbreak of avian flu or other deadly influenza strain. The U.S. congress has recently budgeted over $4 billion to build a stockpile of the yellow pills and similar drugs.
A head-to-head comparison between Nigiro™ Blue Tint and the yellow pills was recently conducted at the School of Medical Technology of Chang Gung University in Taiwan. The study tested four types of virus, including type A Influenza, the broad class of flu virus that contains the Influenza H1N1, Avian H5N1 and strain. The study found that Nigiro Blue Tint™ was more than 12 times as effective as the yellow pills at inhibiting damaging viral activity. At the same time, Nigiro™ Blue Tint was shown to be more than 3 times less toxic to cells than The yellow pills.
Nigiro Blue Tint™ was tested on experimental cells in vitro and also in vivo, in mice inoculated with three progressively increasing concentrations of Influenza A infection. The results were dramatic. The following images graphically illustrate the viral firewall protection afforded by Nigiro™ Blue Tint:
|1. Healthy cells, not exposed to infection||2. Cells infected with influenza virus A H1N1||3. Infected cells protected by Nigiro™ Blue Tint are unharmed|
The first picture shows a field of normal cells that were not exposed to flu virus and retain their characteristic structure. The second picture shows cells that have been ravaged by the damaging cytopathic effects of influenza infection. The final picture shows cells exposed to the exact same conditions as those in the second picture. In this case, however, Nigiro™ Blue Tint’s firewall effect protected them from damage. These cells look identical to the healthy cells in the first picture.
NAILING DOWN THE NUMBERSWhile these images are visually dramatic, the study also recorded objective, numerical results known as IC50 and LC50. Simply put, IC50 is the concentration of a substance needed to inhibit 50% of the virus’s activity. A lower IC50 value is desirable because it means that a smaller concentration of substance is required to achieve a given benefit.
Similarly, LC50 refers to the concentration of a substance that kills 50% of the cells to which it is exposed. Higher values of LC50 are desirable because they mean that the cells can withstand a larger exposure to the substance before sustaining this damage. Low IC50 values suggest that a remedy is effective – high LC50 values suggest that it is safe. The ratio of a remedy’s LC50 value to its IC50 value tells you how far apart the substance’s effective dosage is from its toxic dosage. Again, like LC50, the larger this number is, the better.
The best way to understand these relationships is to compare Nigiro™ Blue Tint with a known and respected anti-viral drug such as the yellow pills. The study compared the ability of The yellow pills and Nigiro™ Blue Tint to inhibit the formation of viral plaque – colonies of virus particles that accumulate when a virus has successfully infected and corrupted host cells.
The following table shows the results of comparing the inhibition of viral plaque in MDCK cells infected with Influenza A. MDCK cells are a well-known reference cell line frequently used in the laboratory for pharmaceutical testing.
Inhibition of Viral Plaque - Nigiro™ Blue Tint vs. The yellow pills
Lower is better
Higher is better
Higher is better
|Nigiro™ Blue Tint||0.014||39.46||2818|
|The yellow pills||0.173||12.50||72|
These results clearly show that Nigiro™ Blue Tint was 12.3 times more effective at inhibiting viral plaque than the yellow pills and more than 3 times less toxic to the experimental cells. The ratio of the two values indicates how many 50% effective doses (IC50) are required to create a 50% toxic dose (LC50). Under these experimental conditions Nigiro Blue Tint™ performed almost 40 times better than the yellow pills, requiring more than 2800 times the effective dose before becoming toxic compared with only 72 times for the yellow pills.
To establish the effectiveness of Nigiro™ Blue Tint in living animals, an experiment was performed using mice inoculated with 3 increasing concentrations of type A flu infection (WSN virus H1N1 inoculated at 15, 150 and 1500 plaque forming units - pfu - respectively). Half of the infected mice were treated with Nigiro™ Blue Tint; the other half was not.
Within 5 days, all of the infected but unprotected mice died – even those inoculated with the lowest concentration of the virus (15 pfu). However, all of the treated mice – including those inoculated with 100 times more flu virus (1500 pfu) – survived maintaining their body weight. A control group, given Nigiro™ Blue Tint but not infected, continued to thrive during the 7 days of the study and showed no ill effects.
In the following table, note how the lines marked dark red, red and pink all end at the bottom of the graph, signifying death of the infected animals. These lines represent the declining weight and health of those mice inoculated, respectively, with 15, 150 and 1500 pfu of the flu virus. The most heavily infected group, marked dark red line on the graph, died within 2 days while the most lightly infected group, marked pink line, died within 5 days.
Conversely, the lines marked green, light green and blue represent the three groups of mice inoculated with the same levels of flu virus, but also protected with Nigiro™ Blue Tint. These mice, including the most heavily infected, all maintained their body weight and recovered from the infection.
NIGIRO™ BLUE TINT and Hand-Foot-Mouth-Disease (EV71)
Enteroviruses are small RNA viruses that are made of ribonucleic acid (RNA) and protein (belong to the family Picornaviridae).
Coxsackieviruses A1-A24 (no A23), and B1-B6
Echoviruses 1-34 (no 10 or 28)
Enteroviruses usually cause self-limited infections in children, but sometimes are associated with several human and mammalian diseases, such as neurological disease and fatal cases of hand-foot-mouth disease (HFMD).
The following diagram shows the relationship of infected cells with the treatment of dosage on EV71:
Nigiro™ Blue Tint can reduce EV71 Plaque Formation
b. Infection without Nigiro™ Blue Tint,
c ~ f: Infection and treatment of 0.0047μM, 0.071 μM, 0.119μM, and 0,238μM of Nigiro™ Blue Tint respectively..
|V: Infected cells
D+V: Addition of Nigiro™ Blue Tint into infected cells
Nigiro™ Blue Tint was also able to delay viral RNA synthesis in the infected cells and to abate the apoptotic process in EV71-infected rhabdomyosarcoma cells with evidence of characteristic DNA fragmentation, decreasing membrane damage and declining cell sub-G1 phase.
Nigiro™ Blue Tint can effectively inhibit EV71 virus adsorption, and prevent virus infection
WHO SHOULD TAKE NIGIRO™ BLUE TINT?>
First, we recommend Nigiro™ Blue Tint for all your mission critical employees.
Next, we strongly recommend Nigiro™ Blue Tint for anyone who travels or comes in contact with the public. Especially travelling to the declared “Affected Country” such as USA, Mexico, Canada, UK, Australia, Japan, Chile and all other countries. Once a flu virus has entered the general population – regardless of whether it’s a simple, seasonal flu or a life-threatening pandemic variant – it becomes extremely difficult to avoid exposure. In the event of a serious outbreak of SWINE flu, Influenza Type A, the Ministry of Health, Singapore recommend staying indoors and avoiding contact with other people. For many of us, following that recommendation in all but the most extreme situations is essentially impossible — our businesses would grind to a halt.
We also recommend Nigiro™ Blue Tint for anyone at heightened risk of exposure to infection. Doctors and nurses, teachers, and a wide variety of service professionals all at risk of exposure from their many contacts during the course of work and business activities.
Naturally, we recommend Nigiro™ Blue Tint for families. Often children are the first to pick up an infection and bring it home from school. By the time they become symptomatic, the infection has already has been transmitted to their parents. Providing children with Nigiro™ Blue Tint as a regular part of their daily nutrition may help to break this cycle, creating a firewall that potentially benefits not only the children themselves but also their parents and, in turn, the entire community of their friends, neighbours and co-workers.
The strikingly beautiful blue of NIGIRO™ BLUE TINT is due to the natural color of phycocyanin
PREVENTION IS BETTER THAN CURING
DIRECTIONS FOR FUTURE RESEARCH
Among the research projects currently underway is a study to accurately characterize and quantify the effectiveness of Nigiro Blue Tint™ against the Influenza type A H1N1 flu virus and Avian Flu H5N1.
CONTACT AND PRODUCT INFORMATION
For more information about Nigiro™ Blue Tint and up-to-date research data and product availability, please visit our website or contact us directly at:
Sole Distributor: Green Energy Singapore Holdings Pte Ltd
Product Inquiry: +65 8321 8800
Email: [email protected]
Copyright © 2009 Green Energy Biotech Corporation Limited.
Nigiro™ Blue Tint is a trademark of Green Energy Singapore Holdings Pte Ltd.
Journal of Medical Virology
Shih SR, Tsai KN, Li YS, Chueh CC, Chan EC. “Inhibition of Enterovirus 71-Induced Apoptosis by Allophycocyanin Isolated From a Blue-Green Alga Spirulina platensis,” Journal of Medical Virology. 2003; 70: 119-125.
Patented Copy Rights in USA since 2002
U.S. Patent 6,346,408 “Method of allophycocyanin inhibition of enterovirus and influenza virus reproduction resulting in cytopathic effect”
|Naturland Organic Cert, Germany||ISO2001:9000||GMP Certificate|
|Reference||Summary of Studies|
|1. Phytother Res. 1993;7:76-80.||Water extract of Spirulina platensis inhibited the replication of Herpes simplex virus type 1 (HSV-1) in Hela cells within the concentration range of 0.8 ~ 50 mg/ml.|
|For HSV-1 corneal infection of hamsters, food containing the extract effectively prolonged the survival time of infected hamsters at doses of 100 and 500 mg/kg.|
|2. J Nat Prod. 1996;59(1):83-7.
3. AIDS Res Hum Retroviruses. 1996;12(15):1463-71.
4. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(1):7-12.
5. Chem Pharm Bull (Tokyo). 2001;49(1):108-10.
|Calcium spirulan (Ca-SP) from Spirulina platensis was found to inhibit the replication of several enveloped viruses, including Herpes simplex virus type 1 (HSV-1), human cytomegalovirus (HCMV), measles virus, mumps virus, influenza A virus, and HIV-1. It revealed that Ca-SP selectively inhibited the penetration of virus into host cells.|
|6. Antiviral Res.
|The antiviral activity of a hot water extract (HWE) of Spirulina maxima was studied by a microplate inhibition assay. The HWE inhibited the infection for: herpes simplex virus type 2 (HSV-2), pseudorabies virus (PRV), human cytomegalovirus (HCMV), and HSV-1, and the ED50 were 0.069, 0.103, 0.142, and 0.333 mg/ml for each virus, respectively. For adenovirus the inhibition was less than 20%, and no inhibition was found for measles virus, subacute sclerosing panencephalitis virus (SSPE), vesicular stomatitis virus (VSV), poliovirus 1 and rotavirus SA-11, at concentrations of 2 mg/ml of the HWE.|
|7. J Med Virol.
|Allophycocyanin (APC) purified from Spirulina sp can neutralize the enterovirus 71 (EV71)-induced cytopathic effect, and inhibit viral plaques formed. Antiviral activity is more efficient in cultures treated with APC before viral infection compared with that in the cultures treated after infection.|